What is claimed is:

1. An expandable intraluminal stent comprising a main body portion having a first end portion, a second end portion, a middle portion and a flow passage defined therethrough, at least a portion of the first end portion having a biocompatible coating.

2. The stent of claim 1 wherein the coating comprises a biocompatible polymer.

3. The stent of claim 1 wherein the coating comprises a biodegradable polymer.

4. The stent of claim 1 wherein the first end portion comprises an inner surface, an outer surface, an end and an edge, the coating covering the end and at least a portion of the edge of the first end portion.

5. The stent of claim 1 wherein at least a portion of the second end portion has a biocompatible coating.

6. The stent of claim 5 wherein the second end portion comprises an outer surface, an inner surface, an end, and an edge, the coating covering the end and at least a portion of the edge of the second end portion.

7. The stent of claim 5 wherein the coating comprises a biocompatible polymer.

8. The stent of claim 1 wherein the coating includes a drug.

9. The stent of claim 8 wherein the drug comprises TAXOL.

10. The stent of claim 1 wherein the coating includes a bioadhesive.

11. The stent of claim 1 wherein the coating comprises a plurality of layers.

12. The stent of claim 11 wherein the plurality of layers is comprised of the same coating material.

13. The stent of claim 11 wherein the plurality of layers is comprised of different coating materials.

14. The stent of claim 12 wherein at least one of the layers includes a drug.

15. The stent of claim 5 wherein the coating comprises a plurality of layers.

16. The stent of claim 15 wherein the plurality of layers is comprised of the same coating material.

17. The stent of claim 15 wherein the plurality of layers is comprised of different materials.

18. The stent of claim 15 wherein at least one of the layers includes a drug.

19. An expandable intraluminal stent comprising a main body portion having a first end portion, a second end portion, a middle portion and a flow passage defined therethrough, and a sleeve of biocompatible material connected to the first end portion.

20. The stent of claim 19 wherein the sleeve comprises a biocompatible polymer.

21. The stent of claim 19 wherein the coating comprises a biodegradable polymer.

22. The stent of claim 19 wherein the sleeve includes apertures.

23. The stent of claim 19 wherein the sleeve includes a drug.

24. The stent of claim 23 wherein the drug comprises TAXOL.

25. The stent of claim 19 wherein the sleeve comprises a plurality of layers.

26. The stent of claim 25 wherein the plurality of layers is comprised of the same coating material.

27. The stent of claim 25 wherein the plurality of layers is comprised of different materials.

28. The stent of claim 25 wherein at least one of the layers includes a drug.

29. The stent of claim 19 further comprising a second sleeve connected to the second end portion.

30. The stent of claim 29 wherein the sleeve comprises a biocompatible polymer.

31. The stent of claim 29 wherein the sleeve includes apertures.

32. The stent of claim 29 wherein the sleeve includes a drug.

33. The stent of claim 29 wherein the sleeve comprises a plurality of layers.

34. The stent of claim 33 wherein the plurality of layers is comprised of the same coating material.

35. The stent of claim 33 wherein the plurality of layers is comprised of different materials.

36. The stent of claim 33 wherein at least one of the layers includes a drug.

37. An expandable intraluminal stent comprising a main body portion having a first end portion, a second end portion, a middle portion and a flow passage defined therethrough, the first end portion being polished to provide a smooth first end portion.

38. The stent of claim 37 further comprising a polished second end portion to provide a smooth second end portion.

39. An expandable intraluminal stent comprising a main body portion having a first end portion, a second end portion, a middle portion and a flow passage defined therethrough, the first end portion being heat treated to provide flexibility.

40. The stent of claim 39 further comprising a heat treated second end portion to provide flexibility.

41. An expandable intraluminal stent comprising a main body portion having a first end portion, a second end portion, a middle portion and a flow passage defined therethrough, the first end portion constructed in a manner so as to be more flexible than the middle portion.

42. The stent of claim 41 wherein the stent comprises a looser mesh first end portion than the middle portion.

43. The stent of claim 41 further comprising the second end portion constructed in a manner so as to be more flexible than the middle portion.

44. The stent of claim 43 wherein the stent comprises a looser mesh second end portion than the middle portion.

45. The stent of claim 1 wherein the coating comprises an RGD peptide-containing compound.

46. The stent of claim 8 wherein the drug comprises 5-flroracil.

47. The stent of claim 8 wherein the drug comprises Tranilast.

48. The stent of claim 8 wherein the drug comprises Tropidil.

49. The stent of claim 8 wehrien the drug comprises Probucol.